HK Stock Market Move | Simcere Pharma (02096) rose more than 3% in the afternoon recently because they have entered into an exclusive promotion service agreement with Puqi Pharmaceutical for the gel of Pumeixi Tini.
China Resources Pharmaceutical Group (02096) rose more than 3% in the afternoon, as of press time, up 3.03% to HK$9.87, with a turnover of HK$40.0982 million.
SIMCERE PHARMA (02096) rose more than 3% in the afternoon, closing at a 3.03% increase to HK$9.87 with a trading volume of HK$40.0982 million.
In recent news, SIMCERE PHARMA announced that the group has entered into an exclusive promotion service agreement with Beijing Puxi Pharmaceutical Technology Co., Ltd. (Puxi Pharmaceutical) for Pumeixi tine gel. According to the agreement, the group will have the exclusive promotion rights for Pumeixi tine gel in the field of skin diseases in mainland China, Hong Kong, and Macau.
Currently, the new drug market application for Pumeixi tine gel for adults and adolescents with atopic dermatitis (AD) indication has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. This cooperation will further strengthen the group's product layout in the field of autoimmune diseases.
Related Articles
HK Stock Market Move | TRIGIANT (01300) closes up more than 6% to hit a record high, with a year-to-date accumulated increase of up to 11 times.
HK Stock Market Move | LIVZON PHARMA (01513) saw a nearly 4% increase in the final trading session. The application for the market approval of Lai Kang Qita Monoclonal Antibody Injection has been accepted.
Thousands of questions are online to launch the first full-cycle college entrance examination volunteer fill-in Agent in China, providing free services to all students nationwide.
HK Stock Market Move | TRIGIANT (01300) closes up more than 6% to hit a record high, with a year-to-date accumulated increase of up to 11 times.
HK Stock Market Move | LIVZON PHARMA (01513) saw a nearly 4% increase in the final trading session. The application for the market approval of Lai Kang Qita Monoclonal Antibody Injection has been accepted.
Thousands of questions are online to launch the first full-cycle college entrance examination volunteer fill-in Agent in China, providing free services to all students nationwide.
RECOMMEND
